0
Signin
countryflagUS

18889881171

AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%

Iteos Therapeutics Inc

Healthcare US ITOS

10.6USD
0.03(0.28%)

Last update at 2024-04-25T20:00:00Z

Day Range

10.2610.62
LowHigh

52 Week Range

8.2023.00
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax 148.74M 256.46M -38.09000M -22.33500M -18.04600M
Minority interest - - - - -
Net income 96.65M 214.52M -38.03300M -22.45400M -18.05700M
Selling general administrative 43.95M 40.51M 15.34M 8.84M 4.31M
Selling and marketing expenses - - - - -
Gross profit 267.63M 344.77M - - -
Reconciled depreciation 0.80M 0.60M 0.54M 0.61M 0.51M
Ebit 126.32M 244.90M -45.24000M -28.04800M -17.98000M
Ebitda 130.39M 255.69M -38.77200M -21.72400M -17.47500M
Depreciation and amortization 4.07M 10.78M 6.47M 6.32M 0.51M
Non operating income net other 19.15M 1.38M -0.04800M - -
Operating income 126.32M 244.90M -45.24000M -28.04800M -21.50100M
Other operating expenses 138.04M 89.69M 39.31M 23.27M 17.82M
Interest expense -19.14900M 1.38M 1.22M 0.00000M 0.07M
Tax provision 52.08M 41.94M -0.05700M 0.12M 0.01M
Interest income 11.36M - - - 0.07M
Net interest income 11.36M - - 0.00000M -0.06600M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 52.08M 41.94M -0.05700M 0.12M 0.01M
Total revenue 267.63M 344.77M 0.00000M 0.00000M 0.00000M
Total operating expenses 138.04M 89.69M 39.31M 23.27M 17.82M
Cost of revenue - - - - -
Total other income expense net 22.41M 11.56M 7.15M 5.71M -0.16300M
Discontinued operations - - - - -
Net income from continuing ops 96.65M 214.52M -38.03300M -22.45400M -18.05700M
Net income applicable to common shares 96.65M 214.52M -43.40200M -26.53500M -20.06600M
Preferred stock and other adjustments - - 0.25M - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 754.99M 884.71M 344.56M 30.74M 27.39M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 12.70M 24.17M 3.22M 0.88M 0.53M
Total liab 91.66M 331.89M 21.36M 15.07M 12.34M
Total stockholder equity 663.33M 552.82M 323.20M 15.67M 15.05M
Deferred long term liab - - - - -
Other current liab 19.73M 17.16M 7.49M 5.40M 1.26M
Common stock 0.04M 0.04M 0.04M 0.00100M 0.09M
Capital stock 0.04M 0.04M 0.04M 51.76M 25.82M
Retained earnings 237.28M 140.62M -73.89800M -35.86500M -10.76500M
Other liab 45.82M 23.20M 6.36M 1.88M 7.32M
Good will - - - - -
Other assets 1.70M 2.60M 3.66M 3.33M 2.56M
Cash 284.80M 848.54M 336.33M 19.87M 21.99M
Cash and equivalents - - - - -
Total current liabilities 42.00M 304.12M 15.00M 13.20M 5.01M
Current deferred revenue 13.78M 281.05M 4.49M 2.36M 0.39M
Net debt -280.13000M -843.19600M -336.32600M -19.86800M -21.98800M
Short term debt 0.84M 0.77M - 4.26M 2.00M
Short long term debt - - - - -
Short long term debt total 4.67M 5.34M - - -
Other stockholder equity 435.67M 413.18M 51.88M 53.61M 0.01M
Property plant equipment 2.12M 2.07M 1.35M 1.34M 1.16M
Total current assets 628.30M 874.71M 339.54M 26.08M 23.67M
Long term investments 118.22M - - - -
Net tangible assets 663.33M 552.82M 323.20M -36.08800M -10.67800M
Short term investments 328.36M - - - -
Net receivables 2.44M 12.09M 0.33M 5.33M 1.16M
Long term debt - - - - -
Inventory - -10.08600M -0.32500M - -
Accounts payable 7.66M 5.14M 3.03M 1.17M 1.37M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -9.64400M -1.01800M 0.62M -0.22400M -0.01100M
Additional paid in capital - - - - -
Common stock total equity 0.04M 0.04M 0.04M 0.00100M 0.09M
Preferred stock total equity - - - - -
Retained earnings total equity 237.28M 140.62M -73.89800M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.70M 2.60M 3.66M 3.33M 2.56M
Deferred long term asset charges - - - - -
Non current assets total 126.69M 10.00M 5.01M 4.67M 3.72M
Capital lease obligations 4.67M 5.34M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -445.00400M -1.24200M -0.37700M -0.92600M -0.29900M
Change to liabilities -261.77300M 293.37M 3.46M 1.82M -1.66900M
Total cashflows from investing activities -446.06200M -1.24200M -0.37700M -0.92600M -0.29900M
Net borrowings 1.06M 0.72M 4.05M - -
Total cash from financing activities 1.98M 3.66M 340.34M 22.54M 23.51M
Change to operating activities 29.87M 11.83M 5.87M -2.90600M -1.27400M
Net income 96.65M 214.52M -38.03300M -22.45400M -18.05700M
Change in cash -563.79700M 512.38M 316.46M -2.06400M 3.24M
Begin period cash flow 848.84M 336.45M 19.99M 22.05M 18.82M
End period cash flow 285.04M 848.84M 336.45M 19.99M 22.05M
Total cash from operating activities -111.19300M 513.14M -25.17600M -23.14500M -19.09700M
Issuance of capital stock - 0.00000M 339.02M 22.37M 23.56M
Depreciation 0.80M 0.60M 0.54M 0.61M 0.51M
Other cashflows from investing activities -0.12000M -0.06100M -0.02100M -0.20500M -0.07300M
Dividends paid - - - - -
Change to inventory - - - - -1.27400M
Change to account receivables - - 5.17M 0.00000M 1.09M
Sale purchase of stock 0.93M 2.94M -0.33200M 0.00000M -0.22600M
Other cashflows from financing activities 1.06M 3.66M 127.01M 22.54M 23.73M
Change to netincome 21.56M 13.79M 2.99M -0.22000M 0.31M
Capital expenditures 0.94M 1.18M 0.36M 0.72M 0.23M
Change receivables - - - - -
Cash flows other operating 31.56M -14.06100M 3.59M - -
Exchange rate changes - -3.17600M 1.68M - -
Cash and cash equivalents changes -555.27100M 512.38M 316.46M - -
Change in working capital -228.49100M 284.21M 9.33M -1.08200M -1.85600M
Stock based compensation 21.56M 13.79M 4.29M 0.81M 0.11M
Other non cash items -1.71800M 0.01M -0.03500M -0.01000M 0.07M
Free cash flow -112.13100M 511.96M -25.53200M -23.86600M -19.32300M

Fundamentals

  • Previous Close 10.57
  • Market Cap387.55M
  • Volume170885
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-91.19000M
  • Revenue TTM66.50M
  • Revenue Per Share TTM1.86
  • Gross Profit TTM 267.63M
  • Diluted EPS TTM-1.75

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ITOS
Iteos Therapeutics Inc		 0.03 0.28% 10.60 - 12.56 5.80 0.64 0.01 2.39
NVO
Novo Nordisk A/S		 -0.37 0.29% 125.79 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -3.3 2.60% 123.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.06 0.76% 397.70 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.06 0.07% 90.16 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc"R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.

Iteos Therapeutics Inc

321 Arsenal Street, Cambridge, MA, United States, 02472-5710

Key Executives

Name Title Year Born
Dr. Michel Detheux Ph.D. Pres, CEO & Director 1966
Mr. Matthew A. Call M.B.A. Chief Operating Officer 1973
Dr. Joanne Jenkins-Lager M.D. Chief Medical Officer 1972
Mr. Matthew Gall Chief Financial Officer 1977
Dr. Yvonne McGrath Ph.D. Chief Scientific Officer 1974
Mr. Ryan Baker Head of Investor Relations NA
Mr. Phillipe Brantegem Vice-Pres of HR NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).